Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up Journal Article
| Authors: | Barakat, R. R.; Sabbatini, P.; Bhaskaran, D.; Revzin, M.; Smith, A.; Venkatraman, E.; Aghajanian, C.; Hensley, M.; Soignet, S.; Brown, C.; Soslow, R.; Markman, M.; Hoskins, W. J.; Spriggs, D. |
| Article Title: | Intraperitoneal chemotherapy for ovarian carcinoma: Results of long-term follow-up |
| Abstract: | Purpose: To determine long-term survival and predictors of recurrence in a retrospective cohort of patients with epithelial ovarian cancer treated with intraperitoneal (IP) chemotherapy. Patients and Methods: Records were reviewed of 433 patients who received IP therapy for ovarian cancer between 1984 and 1998; follow-up data were available for 411 patients. IP therapy was provided as consolidation therapy (n = 89), or for treatment of persistent (n = 310) or recurrent (n = 12) disease after surgery and initial systemic therapy; therapy usually consisted of platinum-based combination therapy. Statistical analysis included tests for associations between potential prognostic factors, and between prognostic factors and survival. Survival probabilities were estimated by Kaplan-Meier methods, and prognostic factors for survival were evaluated by a Cox proportional hazard model. Results: The mean age of patients was 52 years (range, 25 to 76 years). Distribution by stage and grade was as follows: stage I, 7; II, 24; III, 342; IV, 52; not available (NA), 8; and grade 1, 30; 2, 99; and 3, 289; NA, 15. The median survival from initiation of IP therapy by residual disease was none, 8.7 years; microscopic, 4.8 years; less than 1 cm, 3.3 years; more than 1 cm, 1.2 years. In a multivariate analysis, the only significant predictors of long-term survival were grade and size of residual disease at initiation of IP therapy. Conclusion: Prolonged survival was observed in selected patients receiving IP platinum-based therapy. It is not possible to determine the contribution of IP therapy to survival in this study. A relationship between size of disease at the initiation of IP therapy and long-term survival was demonstrated. © 2002 by American Society of Clinical Oncology. |
| Keywords: | adult; cancer survival; treatment outcome; aged; middle aged; retrospective studies; major clinical study; cancer recurrence; fluorouracil; cancer combination chemotherapy; gemcitabine; paclitaxel; combined modality therapy; cytarabine; cancer staging; follow up; follow-up studies; antineoplastic agent; neoplasm staging; cancer grading; intraoperative care; adenocarcinoma; ovarian neoplasms; ovary cancer; etoposide; minimal residual disease; mitoxantrone; ovary carcinoma; platinum; multivariate analysis; kaplan meier method; floxuridine; humans; prognosis; human; female; priority journal; article |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 20 |
| Issue: | 3 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2002-02-01 |
| Start Page: | 694 |
| End Page: | 698 |
| Language: | English |
| DOI: | 10.1200/jco.20.3.694 |
| PUBMED: | 11821450 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 14 November 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work